Clinical significance of plasma metastin level in pancreatic cancer patients
Clinical significance of plasma metastin level in pancreatic cancer patients
复制标题
DOI：
10.3892/or_00000289
复制
发表时间：
2009-03-01
期刊：
影响因子：
4.2
通讯作者：
Fujii, Nobutaka
中科院分区：
文献类型：
--
作者：
Katagiri, Fumihiko;Nagai, Kazuyuki;Fujii, Nobutaka
Metastin是KiSS-1基因编码的54个氨基酸残基的多肽，是G蛋白偶联的C C受体GPR 54的内源性配体。Metastin抑制恶性肿瘤转移并调节促性腺激素释放激素的分泌。metastin的生理作用一直是肿瘤学研究的热点。据报道，KiSS-1基因在胰腺癌中的表达低于正常胰腺组织，而编码GPR 54的hOT 7 T175基因的表达高于正常胰腺组织，但尚无研究探讨胰腺癌患者的临床病理特征与血浆metastin浓度之间的关系。本研究旨在探讨胰腺癌患者血浆转移素样免疫反应物质（LI）水平与临床特征的关系。33名在治疗前或治疗后不久病理学确诊的胰腺癌患者和24名健康志愿者被纳入研究。根据国际抗癌联合会TNM分类对患者进行分组。酶免疫法测定血浆metastin-LI。与健康志愿者相比，癌症患者的血浆metastin-LI水平显著较高。血浆metastin-LI水平与肿瘤大小、浸润深度、淋巴结转移、远处转移等临床病理因素无明显相关性。血浆metastin水平可能是预测胰腺癌存在的重要生物标志物，可用于胰腺癌筛查。
Metastin, which is a 54-residue peptide coded by KiSS-1 gene, is an endogenous ligand to a G-protein-coupled C C receptor GPR54. Metastin suppresses a malignant tumor to metastasize and regulates secretion of gonadotropine releasing hormone. Physiological action of metastin has been focused on in oncology. It is reported that less KiSS-1 gene and more hOT7T175 gene which codes GPR54 are expressed in pancreatic cancers than in normal pancreatic tissues; however, there is no study that investigates the relationship between clinicopathological characteristics and plasma metastin concentration in pancreatic cancer patients. The purpose of this study was to investigate the relationship between plasma metastin-like immunoreactive substance (LI) levels and clinical characteristics in pancreatic cancer patients. Thirty-three patients with pathologically confirmed pancreatic cancer before or just after treatments and 24 healthy volunteers were included in the study. Patients were grouped according to the International Union Against Cancer TNM classification. Plasma metastin-LI was measured by enzyme immunoassay. The plasma metastin-LI levels of cancer patients were significantly higher when compared with healthy volunteers. Significant relationship was not found between the plasma metastin-LI levels and the clinicopathological factors such as tumor size, invasion, lymph node metastasis and distant metastasis. The plasma metastin levels may be a significant biomarker to predict the presence of pancreatic cancer and could be used in pancreatic cancer screening.